替尼泊甙－司莫司汀治疗颅内恶性肿瘤临床观察  

VM-26 PLUS MeCCNU IN THE TREATMENT OF MALIGNANT INTRACRANIAL TUMOR

作　　者：江丰收[1] 庄建生[1] 林新民[1] 胡冰[1] 鲁敏[1] 

机构地区：[1]安徽省立医院肿瘤科

出　　处：《中国癌症杂志》1996年第3期169-171,共3页China Oncology

摘　　要：目的评价替尼泊甙－司莫司汀（ＶＭ－２６—ＭｅＣＣＮＵ）联合方案治疗颅内恶性肿瘤的效果。方法经病理确诊的颅内恶性肿瘤６０例，随机分为两组。治疗组３０例，采用ＶＭ－２６—ＭｅＣＣＮＵ方案；对照组３０例，采用依托泊甙－司莫司汀（ＶＰ－１６—ＭｅＣＣＮＵ）方案。５天为一个周期，每个周期间隔４周，连续４个周期。观察指标包括临床症状和体征、头颅ＣＴ或ＭＲＩ检查。随访时间４～１２个月以上。结果治疗组与对照组的总有效率分别为６３．３％和３６．６％（Ｐ＜０．０５）。结论ＶＭ－２６—ＭｅＣＣＮＵ序列治疗颅内恶性肿瘤是一种安全有效的化疗方案。To evaluate the therapeutic effect of VM-26 plus MeCCNU in the treatment of patientswith malignant intracranial tumor.METHODS A randomied clinical trial of VM-26 plus MeCCNU versus VP-16 plus MeCCNU wascarried out. 30 patients with malignant intracranial tumors verified by pathology were treated with 4 cyclesof VM-26 plus MeCCNU at monthly intervals,the other 30 patients with 4 cycles of VP-16 plus MeCCNUat monthly intervals. The observation critieriae were clinical symptoms,physical signs and CT or MRI scanchanges,the follow-up time was from 4 to 12 months.RESULTS The efficacy in the VM-26 group was better than the VP-16 group, responses being 63.3% vs 36. 6% (P<0. 05).CONCLUSIONS VM-26 plus MeCCNU can be considered to be a safe and efficacious chemotherapyregime in the treatment of malignant intracranial tumors.

关 键 词：脑肿瘤 替尼泊甙 司莫司汀 药物疗法 

分 类 号：R739.41[医药卫生—肿瘤]